Skip to content

A Prospective Randomized Controlled Study on the Clinical Efficacy and Safety of Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) for Treating High-Altitude Hypertension

Research on Health Management Prevention and Treatment of Hypertension in Plateau Environments Based on TCM Constitution Theory

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2025001488
Enrollment
Unknown
Registered
2025-07-26
Start date
2026-03-01
Completion date
Unknown
Last updated
2026-02-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

high-altitude hypertension

Interventions

Sponsors

Jibengang Subdistrict Health Service Center Chengguan District Lhasa City Tibet Autonomous Region
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Meets the hypertension diagnostic criteria recommended by the 2024 ESC Guidelines for the management of elevated blood pressure and hypertension (multiple non-concurrent measurements of systolic blood pressure =140 mmHg and/or diastolic blood pressure =90 mmHg); 2. Resides at an altitude =3000 meters during the study period; 3. Resided at an altitude =3000m for =6 months; 4. Aged between 18 and 80 years; 5. Did not participate in any other clinical trials within the past 3 months; 6. Voluntarily agreed to participate in this study and signed an informed consent form.

Exclusion criteria

Exclusion criteria: 1. Individuals with inflammation, skin damage, or scarring in the concha cavity; 2. Patients with secondary hypertension, or those with implanted electronic devices such as pacemakers, accompanied by severe orthostatic hypotension, hypertensive emergencies, or subacute hypertensive conditions; 3. Individuals with progressive encephalopathy, progressive neurological disorders, or other severe conditions: malignant tumors, cognitive impairment, or psychiatric disorders; 4. Individuals who have recently received corticosteroid hormone therapy or other medications that may affect the central nervous system; 5. Individuals with severe cardiovascular, cerebrovascular, respiratory, or digestive system diseases; 6. Individuals with a history of stroke or myocardial infarction.

Design outcomes

Primary

MeasureTime frame
24-hour mean diastolic blood pressure;24-hour mean systolic blood pressure;

Secondary

MeasureTime frame
Waist Circumference;Echocardiographic Parameters;BMI (Body Mass Index);Peripheral Oxygen Saturation ;Hemoglobin (Hb);Blood Lipids;Traditional Chinese Medicine Syndrome Pattern;24-hour blood pressure variability;Daytime mean systolic blood pressure;Daytime mean diastolic blood pressure;Nighttime mean systolic blood pressure;Nighttime mean diastolic blood pressure;

Countries

China

Contacts

Public ContactDONG Zhouli

Jibengang Subdistrict Health Service Center Chengguan District Lhasa City Tibet Autonomous Region

479750023@qq.com13648987589

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 7, 2026